Medical company Novo Nordisk announced the successful completion of a second phase of trials of a new drug intended to replace conventional insulin in the treatment of type 2 diabetes. The drug is called "insulin icodec" and differs in that after injection it gradually enters the body in equal doses for seven days. And therefore, instead of tedious daily injections, it will be possible to inject the medicine only once a week.
Insulin Icodec is a significant achievement of biochemists. First, the insulin molecule itself has been modified and is no longer threatened by enzymatic degradation. Secondly, Icodec is adapted to bond with liver albumin, and this bond prevents it from rapidly dissolving. As a result, one injection is guaranteed to supply the body with insulin over a long period.
Clinical trials during the second phase, when Icodec was administered to 247 patients with type 2 diabetes for 26 weeks, showed the complete success of the concept. Patients did not notice that they received six placebo injections per week and only one icodec, and the treating physicians did not find a difference in results with the control group, who received daily injections. The third stage of testing will begin this year.
The main advantage of Icodec over conventional insulin injections is the organization of the process. Young people have no time, old people confuse medicines, adults have a lot of worries - the need to control their condition and do injections every day is too tiring. But if it is possible to receive just one injection per week, it greatly simplifies the life of patients and the work of those who look after them. And the risk of error is significantly less if you need to make only one injection, and not seven.